Can-Fite BioPharma Ltd. (CANF) Revenue History
Annual and quarterly revenue from 2013 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
Revenue Growth Metrics
CANF Revenue Analysis (2013–2024)
As of March 2, 2026, Can-Fite BioPharma Ltd. (CANF) generated trailing twelve-month (TTM) revenue of $560,000, reflecting significant decline in growth of -36.1% year-over-year. The most recent quarter (Q2 2025) recorded $101,000 in revenue, up 0.0% sequentially.
Looking at the longer-term picture, CANF's 5-year compound annual growth rate (CAGR) stands at -19.8%, indicating revenue contraction over this period. The company achieved its highest annual revenue of $3.8 million in 2018.
When compared to Healthcare sector peers including ARGX (+335.2% YoY), ABVX (+125.1% YoY), and KYMR (-16.7% YoY), CANF has underperformed the peer group in terms of revenue growth. Compare CANF vs ARGX →
Peer Comparison
Compare CANF's revenue metrics with industry peers
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| CANFCurrent | $560,000 | -36.1% | -19.8% | -1206.2% | |
| ARGX | $2.2B | +335.2% | +94.6% | -1.0% | |
| ABVX | $11M | +125.1% | +457.7% | -1602.9% | |
| KYMR | $39M | -16.7% | +2.9% | -891.3% | |
| TGTX | $329M | +31.0% | +364.6% | 12.7% | |
| KNSA | $678M | +60.1% | - | 11.4% |
Historical Revenue Data
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $674K | -9.3% | $674K | 100.0% | $-8,130,000 | -1206.2% |
| 2023 | $743K | -8.3% | $743K | 100.0% | $-8,195,000 | -1103.0% |
| 2022 | $810K | -5.0% | $810K | 100.0% | $-10,096,000 | -1246.4% |
| 2021 | $853K | +11.8% | $853K | 100.0% | $-12,842,000 | -1505.5% |
| 2020 | $763K | -62.5% | $763K | 100.0% | $-14,139,000 | -1853.1% |
| 2019 | $2.0M | -46.8% | $2.0M | 100.0% | $-12,007,000 | -590.9% |
| 2018 | $3.8M | +352.2% | $3.8M | 100.0% | $-5,414,000 | -141.7% |
| 2017 | $845K | +398.4% | $845K | 100.0% | $-7,375,705 | -873.1% |
| 2016 | $170K | +2.9% | $170K | 100.0% | $-8,633,858 | -5093.7% |
| 2015 | $165K | - | $165K | 100.0% | $-6,415,005 | -3894.6% |
See CANF's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CANF Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare CANF vs AGIO
See how CANF stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is CANF's revenue growth accelerating or slowing?
CANF revenue declined -36.1% year-over-year, contrasting with the 5-year CAGR of -19.8%. TTM revenue fell to $560000.00. This reverses the prior growth trend.
What is CANF's long-term revenue growth rate?
Can-Fite BioPharma Ltd.'s 5-year revenue CAGR of -19.8% reflects the variable expansion pattern. Current YoY growth of -36.1% is below this long-term average.
How is CANF's revenue distributed by segment?
CANF reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2013-2024 are available for download. Segment mix reveals concentration and diversification trends.